Biosimilar Inspection Modernization Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill updates how the Food and Drug Administration approaches inspections of biosimilar manufacturing facilities. It defines key terms, requires a public meeting and report on mutual recognition agreements, directs FDA to use more flexible inspection tools such as remote regulatory assessments, and requires a strategic plan for improving domestic biosimilar inspections.
Who Benefits and How
Biosimilar manufacturers could benefit from a more modern, risk-based inspection system that uses alternative tools and clearer planning. Congress would gain more visibility into FDA's inspection approach.
Who Bears the Burden and How
FDA would face new meeting, reporting, process-updating, and strategic-planning duties tied to biosimilar inspection oversight.
Key Provisions
- Defines biosimilar-related inspection terms.
- Requires a public meeting and report on mutual recognition agreements.
- Directs FDA to use more flexible and risk-based inspection tools.
- Requires a strategic plan to improve domestic biosimilar inspections.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Modernize FDA oversight of biosimilar manufacturing inspections through definitions, a public meeting and report on mutual recognition agreements, more flexible inspection tools, and a strategic plan for domestic inspection improvements.
Key Policy Areas
Healthcare, Pharmaceuticals, Government Administration
Primary Purpose
Modernize FDA oversight of biosimilar manufacturing inspections through definitions, a public meeting and report on mutual recognition agreements, more flexible inspection tools, and a strategic plan for domestic inspection improvements.
Policy Domains
Inspection Tool Modernization
Identified Gains
Contextual inference, no direct clause citation- Biosimilar manufacturers
- Food and Drug Administration inspectors using alternative tools
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Food and Drug Administration
Contextual inference, no direct clause citation
Inspection Terms and Reporting
Identified Gains
Contextual inference, no direct clause citation- Congressional overseers
- Biosimilar manufacturers seeking more predictable inspections
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Food and Drug Administration
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMr. Budd (for himself and Ms. Hassan) introduced the following …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Food and Drug Administration, Food and Drug Administration biosimilar inspection program
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services acting through the Commissioner of Food and Drugs
- "the_secretary"
- → Secretary of Health and Human Services acting through the Commissioner of Food and Drugs
Key Definitions
Terms defined in this bill
An establishment engaged in manufacturing or processing a biosimilar biological product and registered under the Federal Food, Drug, and Cosmetic Act.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology